BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
申请人:SINGH Jasbir
公开号:US20120213758A1
公开(公告)日:2012-08-23
The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id:
A particular embodiment is
[EN] BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS<br/>[FR] INHIBITEURS DE BIARYLE PDE4 POUR LE TRAITEMENT DE TROUBLES PULMONAIRES ET CARDIOVASCULAIRES
申请人:DECODE GENETICS EHF
公开号:WO2009067621A1
公开(公告)日:2009-05-28
The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula (Ia), (Ib), (Ic) or (Id). A particular embodiment is formula (I).
[EN] PDE4 INHIBITORS SELECTIVE FOR THE LONG FORM OF PDE4 FOR TREATING INFLAMMATION AND AVOIDING SIDE EFFECTS<br/>[FR] INHIBITEURS DE PDE4 SÉLECTIFS POUR LA FORME LONGUE DE PDE4 POUR TRAITER UNE INFLAMMATION ET ÉVITER DES EFFETS SECONDAIRES
申请人:DECODE GENETICS EHF
公开号:WO2010059838A2
公开(公告)日:2010-05-27
The present invention relates to compounds which are inhibitors of phosphodiesterase-4 (PDE4) useful for the treatment and prevention of stroke, myocardial infarct, cardiovascular inflammatory diseases and disorders and central nervous system disorders, to compounds with a selectivity for a non-catalytic portion of PDE4, to methods of determining this selectivity.
BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
申请人:Singh Jasbir
公开号:US20090136473A1
公开(公告)日:2009-05-28
The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id:
A particular embodiment is